Quick Answer
NORTHWEST BIOTHERAPEUTICS INC reported Stockholders Equity of -$94.49 million for the year ending 2024.
- NORTHWEST BIOTHERAPEUTICS INC showed a decrease of -43.7% in Stockholders Equity from 2023 to 2024.
- This data is from NORTHWEST BIOTHERAPEUTICS INC's annual report (Form 10-K), filed with the SEC on March 31, 2025.
- XBRL data for this metric is available from 2008 to 2024 (17 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q4 2011: -$52.17 million | Q1 2012: -$24.82 million | Q3 2012: -$38.10 million | Q1 2013: -$28.05 million | Q2 2013: -$27.25 million | Q3 2013: -$25.08 million | Q1 2014: -$31.06 million | Q2 2014: -$29.87 million | Q3 2014: -$31.22 million | Q1 2015: -$70.70 million | Q2 2015: -$76.17 million | Q3 2015: -$57.36 million | Q1 2016: -$6.19 million | Q2 2016: -$18.97 million | Q3 2016: -$5.02 million | Q1 2017: -$36.64 million | Q2 2017: -$35.24 million | Q3 2017: -$42.83 million | Q1 2018: -$80.82 million | Q2 2018: -$84.30 million | Q3 2018: -$47.14 million | Q1 2019: -$58.50 million | Q2 2019: -$54.24 million | Q3 2019: -$55.90 million | Q1 2020: -$36.58 million | Q2 2020: -$83.01 million | Q3 2020: -$212.43 million | Q1 2021: -$353.20 million | Q2 2021: -$349.84 million | Q3 2021: -$301.73 million | Q1 2022: -$120.53 million | Q2 2022: -$91.67 million | Q3 2022: -$108.85 million | Q1 2023: -$55.98 million | Q2 2023: -$61.03 million | Q3 2023: -$70.06 million | Q4 2023: -$65.77 million | Q1 2024: -$73.28 million | Q2 2024: -$76.50 million | Q3 2024: -$80.12 million | Q4 2024: -$94.49 million | Q1 2025: -$99.48 million | Q2 2025: -$100.39 million | Q3 2025: -$108.65 million.
- Over the full 17 years of available data (2008 to 2024), NORTHWEST BIOTHERAPEUTICS INC's Stockholders Equity has declined by 668.2%.
- Historical annual values: Fiscal year 2024: -$94.49 million | Fiscal year 2023: -$65.77 million | Fiscal year 2022: -$128.10 million | Fiscal year 2021: -$123.99 million | Fiscal year 2020: -$362.95 million | Fiscal year 2019: -$45.06 million | Fiscal year 2018: -$48.13 million | Fiscal year 2017: -$67.33 million | Fiscal year 2016: -$26.50 million | Fiscal year 2015: -$4.68 million | Fiscal year 2014: -$35.03 million | Fiscal year 2013: -$9.82 million | Fiscal year 2012: -$16.07 million | Fiscal year 2011: -$52.17 million | Fiscal year 2010: -$27.68 million | Fiscal year 2009: -$20.69 million | Fiscal year 2008: -$12.30 million.
- Data sourced from SEC EDGAR public filings as of August 8, 2026.
Last verified: